tiprankstipranks
Trending News
More News >

Elevation Oncology downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth downgraded Elevation Oncology (ELEV) to Neutral from Buy with a 36c price target down from $1.0, after the company entered into a definitive merger agreement with Concentra Biosciences that includes a proposal to be acquired for a purchase price of 36c per share in cash.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1